MedTrace Logo

Treatment Effect of Intense Pulsed Light and Thermal Pulsation Therapy on Meibomian Gland Dysfunction-associated Dry Eye Disease: a Randomized Trial

NCT06745089 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-12-20

No results posted yet for this study

Summary

The goal of this clinical trial is to understand novel treatment methods for meibomian gland dysfunction (MGD)-associated dry eye disease (DED) by comparing two treatment modalities- intense pulsed light (IPL) and thermal pulsation therapy (TPT), to find out the difference of their therapeutic mechanisms and treatment effects, so that eye doctors can give more precise advice to the patients when making treatment decisions.

The main questions it aims to answer are:

* What subtype of meibomian gland dysfunction (MGD) better responds to which treatment modality?
* How long do the treatment effects last?

Researchers will compare each group (IPL and TPT) to a control group treated with eyedrops.

\* Do combined treatment of IPL or TPT with eyedrops show better outcomes than only eyedrops?

Participants will:

* Receive different treatment for 2 months according to the group they were randomly allocated to.
* Visit the clinic for checkups after 1 and 3 months after completing the treatment sessions.

Conditions

  • Dry Eye Disease (DED)
  • Meibomian Gland Dysfunction

Interventions

DEVICE

Intense pulsed light

Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.

DEVICE

thermal pulsation therapy

Thermal pulsation therapy utilizes local heating and massage on the eyelids.

DRUG

Ocular lubricant

Ocular lubricants moisturize the ocular surface.

Sponsors & Collaborators

  • Nobel Eye Institute

    collaborator UNKNOWN

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • National Health Research Institutes, Taiwan

    collaborator OTHER

  • National Yang Ming Chiao Tung University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-13
Primary Completion
2023-06-21
Completion
2024-03-10

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745089 on ClinicalTrials.gov